Literature DB >> 12692887

Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats.

Tomoaki Nagao1, Tadatoshi Tanino, Masahiro Iwaki.   

Abstract

To determine the effect of arthritis on the disposition of flurbiprofen (FP) and its acyl glucuronide (FPG) as well as formation of covalent adducts with plasma protein, a pharmacokinetic study was carried out in adjuvant-induced arthritic (AA) rats. In control animals the pharmacokinetics of FP were stereoselective following intravenous bolus injection of rac-FP: (-)-(R)-FP showed higher plasma clearance (CL(tot)) and shorter mean residence time (MRT) compared to (+)-(S)-FP. The CL(tot) and clearance for the glucuronide formation (CL(glu)) of both enantiomers in AA rats were extremely increased compared to those in control rats. Increased total clearance in AA rats was due, at least in part, to a remarkable increase in the plasma unbound fraction of FP, consistent with a decrease in the plasma albumin level. The yield of covalent binding of FP to plasma protein in AA rats was less than that in controls, being consistent with the decrease in the plasma acyl glucuronide level. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692887     DOI: 10.1002/chir.10227

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  2 in total

1.  Metabolic profiling of praziquantel enantiomers.

Authors:  Haina Wang; Zhong-Ze Fang; Yang Zheng; Kun Zhou; Changyan Hu; Kristopher W Krausz; Dequn Sun; Jeffrey R Idle; Frank J Gonzalez
Journal:  Biochem Pharmacol       Date:  2014-05-10       Impact factor: 5.858

2.  Stereoselective Covalent Adduct Formation of Acyl Glucuronide Metabolite of Nonsteroidal Anti-Inflammatory Drugs with UDP-Glucuronosyltransferase.

Authors:  Atsushi Kawase; Rio Yamashita; Tsubasa Yoshizato; Mashiro Yoshikawa; Hiroaki Shimada; Masahiro Iwaki
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.